bintrafusp alfa

INTR@PID CLINICAL TRIALS™

Investigating the effect of bintrafusp alfa, a bifunctional fusion protein designed for colocalized, simultaneous inhibition of the TGF-β and PD-L1 pathways, in multiple cancer types.

Bintrafusp alfa is under clinical investigation and has not been proven to be safe and effective. There is no guarantee that bintrafusp alfa will be approved in the sought-after indication by any health authority worldwide.

INTR@PID™ LUNG 005[1] Now Enrolling

STAGE III NSCLC | PHASE 2 RANDOMIZED | COMBINATION THERAPY

INTR@PID LUNG 005 (NCT03840902) is a phase 2, randomized, controlled study evaluating bintrafusp alfa with concurrent chemoradiation therapy (cCRT) followed by bintrafusp alfa vs placebo with cCRT followed by durvalumab for the treatment of patients with unresectable stage III non-small cell lung cancer (NSCLC).

Study design | Global



Key inclusion criteria§

- Participants must have histologically documented stage III locally advanced, unresectable NSCLC and adequate pulmonary function

Key exclusion criteria§

- Participants must not have mixed small cell lung cancer with NSCLC histology or received prior systemic cytotoxic chemotherapy for NSCLC or therapy targeting T-cell coregulatory proteins

*Until unacceptable toxicity or investigator-assessed confirmed disease progression. †cCRT consists of intensity-modulated radiation therapy in combination with chemotherapy (cisplatin + etoposide, cisplatin + pemetrexed, or carboplatin + paclitaxel). ‡Or for up to 1 year after cCRT. §For a full list of inclusion and exclusion criteria, please visit www.clinicaltrials.gov.

cCRT, concurrent chemoradiation therapy; DOR, duration of response; IV, intravenous; NSCLC, non-small cell lung cancer; OR, objective response; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival; Q2W, every 2 weeks; R, randomized; TGF-β, transforming growth factor β.

Reference: 1. ClinicalTrials.gov. M7824 with cCRT in unresectable stage III non-small cell lung cancer (NSCLC). Accessed March 11, 2021. https://clinicaltrials.gov/ct2/show/NCT03840902.



Are your patients eligible?

For more information, visit
www.intrapidclinicaltrials.com
www.clinicaltrials.gov

EMD SERONO gsk

US-BIN-00078 | March 2021